Naspers' Tencent share sale and the legacy of investor Li Ka-shing indicate the capital generated in Hong Kong in recent years.

Appulse Power, a spinout from University of Toronto, has been acquired by Silanna Semiconductor for an undisclosed sum.

Vermouth brand Belsazar is the first portfolio company of Diageo-backed accelerator Distill Ventures to be acquired by the corporate.

Salesforce has agreed to buy Mulesoft, a portfolio company that has more than doubled in value since its 2017 IPO, in a deal with an enterprise value of $6.5bn.

Boston Scientific has bought Emcision, a spinout from Imperial College London that is developing a range of surgical instruments.

The cancer immunotherapy developer, backed by Stanford University, has closed the offering after the underwriters bought another $18m of shares.

DocuSign, valued at $3bn as of its last funding round, has confidentially filed for an initial public offering that would offer exits to more than a dozen corporate investors.

The cancer immunotherapy developer, backed by GV, Celgene, Novartis and Taiho Ventures, has closed the offering after the underwriters bought another $18m of shares.

The Aptus Therapeutics-backed neurodegenerative disorder drug developer has filed for an $80.5m initial public offering on Nasdaq after raising roughly $30m in VC funding.

Prexton Therapeutics, a Parkinson's disease-focused spinoff of Merck Group that had raised $41m in funding, has agreed to an acquisition that could reach more than $1.1bn in size.